FR19C1017I1 - Modulateurs de transporteurs a cassette de liaison a l'atp - Google Patents
Modulateurs de transporteurs a cassette de liaison a l'atpInfo
- Publication number
- FR19C1017I1 FR19C1017I1 FR19C1017C FR19C1017I1 FR 19C1017 I1 FR19C1017 I1 FR 19C1017I1 FR 19C1017 C FR19C1017 C FR 19C1017C FR 19C1017 I1 FR19C1017 I1 FR 19C1017I1
- Authority
- FR
- France
- Prior art keywords
- atp
- binding cassette
- cassette transporter
- transporter modulators
- modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11214508P | 2008-11-06 | 2008-11-06 | |
US11215208P | 2008-11-06 | 2008-11-06 | |
PCT/US2008/012689 WO2010053471A1 (fr) | 2008-11-06 | 2008-11-12 | Modulateurs de transporteurs à cassette de liaison à l'atp |
Publications (2)
Publication Number | Publication Date |
---|---|
FR19C1017I1 true FR19C1017I1 (fr) | 2019-05-03 |
FR19C1017I2 FR19C1017I2 (fr) | 2019-07-19 |
Family
ID=40933810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR19C1017C Active FR19C1017I2 (fr) | 2008-11-06 | 2019-03-15 | Modulateurs de transporteurs a cassette de liaison a l'atp |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP2940016A1 (fr) |
JP (4) | JP5600322B2 (fr) |
KR (3) | KR101559963B1 (fr) |
CN (2) | CN108117546A (fr) |
AU (1) | AU2008363828B2 (fr) |
BR (1) | BRPI0823228B8 (fr) |
CA (1) | CA2742821C (fr) |
CL (1) | CL2011001027A1 (fr) |
CY (2) | CY1116067T1 (fr) |
DK (1) | DK2365972T3 (fr) |
ES (1) | ES2532753T3 (fr) |
FR (1) | FR19C1017I2 (fr) |
HK (2) | HK1162477A1 (fr) |
HR (1) | HRP20150288T1 (fr) |
HU (1) | HUS1900015I1 (fr) |
IL (3) | IL212737A (fr) |
LT (1) | LTC2365972I2 (fr) |
LU (1) | LUC00110I2 (fr) |
ME (1) | ME02105B (fr) |
MX (2) | MX2011004832A (fr) |
NL (1) | NL300984I9 (fr) |
NO (1) | NO2019015I1 (fr) |
NZ (2) | NZ592694A (fr) |
PL (1) | PL2365972T3 (fr) |
PT (1) | PT2365972E (fr) |
RS (1) | RS53868B1 (fr) |
RU (1) | RU2013157877A (fr) |
SI (1) | SI2365972T1 (fr) |
UA (1) | UA121188C2 (fr) |
WO (1) | WO2010053471A1 (fr) |
ZA (1) | ZA201103883B (fr) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
NZ587551A (en) | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
EP3696174A1 (fr) | 2005-11-08 | 2020-08-19 | Vertex Pharmaceuticals Incorporated | Modulateurs hétérocycliques de transporteurs de cassette à liaison atp |
PL3219705T3 (pl) | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
SI2674428T1 (sl) | 2006-04-07 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Modulatorji transporterjev atp-vezavne kasete |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
CN101687842B (zh) | 2007-05-09 | 2013-03-06 | 沃泰克斯药物股份有限公司 | Cftr调节剂 |
CN103626744B (zh) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
LT2639223T (lt) | 2007-12-07 | 2017-06-26 | Vertex Pharmaceuticals Incorporated | Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas |
ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
UA104876C2 (uk) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
KR101559963B1 (ko) * | 2008-11-06 | 2015-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송자의 조절자 |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
CA2794559C (fr) * | 2010-03-25 | 2019-07-23 | Vertex Pharmaceuticals Incorporated | Formes solides de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
WO2011127241A2 (fr) | 2010-04-07 | 2011-10-13 | Vertex Pharmaceuticals Incorporated | Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yle) cyclopropane carboxamido)-3-méthylpyridin-2-yle) benzoïque et leur administration |
CN103038214B (zh) | 2010-04-22 | 2015-09-30 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
EP3138563A1 (fr) * | 2010-04-22 | 2017-03-08 | Vertex Pharmaceuticals Inc. | Compositions pharmaceutiques et leurs administrations |
NZ603044A (en) * | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
AU2011242454A1 (en) * | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
AU2011293658B2 (en) * | 2010-08-23 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
ME02650B (fr) * | 2011-11-08 | 2017-06-20 | Vertex Pharma | Modulateurs de transporteurs de cassette de liaison à l'atp |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
CA2878057A1 (fr) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Compositions pharmaceutiques de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropane-carboxamide et leur administration |
CN105307655B (zh) | 2013-03-13 | 2019-05-03 | 弗拉特利发现实验室有限责任公司 | 哒嗪酮化合物及其用于制备治疗囊肿状纤维化的药物的应用 |
EP2970468B1 (fr) | 2013-03-13 | 2021-07-07 | Novartis AG | Molécules de liaison à notch2 pour le traitement de maladies respiratoires |
KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
EP2932966A1 (fr) | 2014-04-16 | 2015-10-21 | Novartis AG | Inhibiteurs de la gamma sécrétase pour traiter des maladies respiratoires |
EP3142701B1 (fr) | 2014-05-12 | 2018-06-27 | Verona Pharma PLC | Nouveau traitement |
GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
CN107110831B (zh) | 2014-11-18 | 2020-02-21 | 弗特克斯药品有限公司 | 进行高通量试验高效液相色谱的方法 |
US10167278B2 (en) | 2014-12-31 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
CN105153106B (zh) * | 2015-09-02 | 2017-08-25 | 阜新奥瑞凯新材料有限公司 | 一种2,2‑二氟胡椒酸甲酯的制备方法 |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
JP6601365B2 (ja) | 2016-07-27 | 2019-11-06 | 株式会社デンソー | 制御システム |
SG10201913595YA (en) | 2016-09-30 | 2020-02-27 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
WO2018107100A1 (fr) | 2016-12-09 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
CA3066084A1 (fr) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methodes de traitement de la fibrose kystique |
MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
ES2912657T3 (es) | 2017-08-02 | 2022-05-26 | Vertex Pharma | Procesos para preparar compuestos de pirrolidina |
US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
CA3078893A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
WO2019113476A2 (fr) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
US11066417B2 (en) | 2018-02-15 | 2021-07-20 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators |
EP3774825A1 (fr) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
CN111763198B (zh) * | 2019-04-01 | 2021-09-07 | 新发药业有限公司 | 一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法 |
CA3150162A1 (fr) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
BR112022002606A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Moduladores do regulador de condutância transmembrana da fibrose cística |
US20230057246A1 (en) * | 2020-02-05 | 2023-02-23 | Laurus Labs Limited | Novel processes for preparation of tezacaftor |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
CA3188787A1 (fr) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
EP3970718A1 (fr) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | Nouvelle utilisation médicale des modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique (cftr) |
KR20230104618A (ko) | 2020-10-07 | 2023-07-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막관통 전도도 조절자의 조절제 |
WO2022076618A1 (fr) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20240018161A1 (en) | 2020-10-07 | 2024-01-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076627A1 (fr) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
CR20230198A (es) | 2020-10-07 | 2023-07-03 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
EP4225750A1 (fr) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
WO2022076626A1 (fr) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique |
WO2022076628A1 (fr) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
WO2023150237A1 (fr) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
WO2023150236A1 (fr) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol |
WO2023154291A1 (fr) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
WO2023196429A1 (fr) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
WO2023224924A1 (fr) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Formes solides de composés macrocycliques en tant que modulateurs de cftr et leur préparation |
WO2023224931A1 (fr) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
NZ587551A (en) | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
SI2674428T1 (sl) * | 2006-04-07 | 2016-07-29 | Vertex Pharmaceuticals Incorporated | Modulatorji transporterjev atp-vezavne kasete |
UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
KR101559963B1 (ko) * | 2008-11-06 | 2015-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | Atp-결합 카세트 수송자의 조절자 |
-
2008
- 2008-11-12 KR KR1020117012764A patent/KR101559963B1/ko active IP Right Grant
- 2008-11-12 PL PL08876364T patent/PL2365972T3/pl unknown
- 2008-11-12 EP EP14197820.5A patent/EP2940016A1/fr not_active Withdrawn
- 2008-11-12 EP EP08876364.4A patent/EP2365972B1/fr active Active
- 2008-11-12 NZ NZ592694A patent/NZ592694A/xx not_active IP Right Cessation
- 2008-11-12 BR BRPI0823228A patent/BRPI0823228B8/pt active IP Right Grant
- 2008-11-12 CN CN201711204617.5A patent/CN108117546A/zh active Pending
- 2008-11-12 KR KR1020157006518A patent/KR101587389B1/ko active Application Filing
- 2008-11-12 DK DK08876364.4T patent/DK2365972T3/en active
- 2008-11-12 MX MX2011004832A patent/MX2011004832A/es active IP Right Grant
- 2008-11-12 ES ES08876364.4T patent/ES2532753T3/es active Active
- 2008-11-12 CN CN2008801326311A patent/CN102272127A/zh active Pending
- 2008-11-12 KR KR1020167000956A patent/KR20160013251A/ko not_active Application Discontinuation
- 2008-11-12 WO PCT/US2008/012689 patent/WO2010053471A1/fr active Application Filing
- 2008-11-12 NZ NZ609962A patent/NZ609962A/en unknown
- 2008-11-12 ME MEP-2015-37A patent/ME02105B/me unknown
- 2008-11-12 AU AU2008363828A patent/AU2008363828B2/en active Active
- 2008-11-12 MX MX2013012665A patent/MX357497B/es unknown
- 2008-11-12 JP JP2011535544A patent/JP5600322B2/ja active Active
- 2008-11-12 RS RS20150170A patent/RS53868B1/en unknown
- 2008-11-12 CA CA2742821A patent/CA2742821C/fr active Active
- 2008-11-12 PT PT08876364T patent/PT2365972E/pt unknown
- 2008-11-12 UA UAA201312737A patent/UA121188C2/uk unknown
- 2008-11-12 SI SI200831394T patent/SI2365972T1/sl unknown
-
2011
- 2011-05-05 IL IL212737A patent/IL212737A/en active Pre-grant Review Request
- 2011-05-09 CL CL2011001027A patent/CL2011001027A1/es unknown
- 2011-05-26 ZA ZA2011/03883A patent/ZA201103883B/en unknown
-
2012
- 2012-03-16 HK HK12102660.1A patent/HK1162477A1/xx unknown
-
2013
- 2013-12-25 RU RU2013157877/04A patent/RU2013157877A/ru not_active Application Discontinuation
-
2014
- 2014-07-28 IL IL233837A patent/IL233837A/en active IP Right Grant
- 2014-08-15 JP JP2014165547A patent/JP5728611B2/ja active Active
-
2015
- 2015-03-03 CY CY20151100222T patent/CY1116067T1/el unknown
- 2015-03-16 HR HRP20150288TT patent/HRP20150288T1/hr unknown
- 2015-04-06 JP JP2015077925A patent/JP5905620B2/ja active Active
- 2015-06-30 IL IL239713A patent/IL239713A/en active Protection Beyond IP Right Term
-
2016
- 2016-03-16 JP JP2016052743A patent/JP2016147887A/ja active Pending
- 2016-04-15 HK HK16104342.9A patent/HK1216526A1/zh unknown
-
2019
- 2019-03-13 HU HUS1900015C patent/HUS1900015I1/hu unknown
- 2019-03-15 FR FR19C1017C patent/FR19C1017I2/fr active Active
- 2019-03-21 LT LTPA2019505 patent/LTC2365972I2/lt unknown
- 2019-03-21 LU LU00110C patent/LUC00110I2/fr unknown
- 2019-04-04 NO NO2019015C patent/NO2019015I1/no unknown
- 2019-04-29 NL NL300984C patent/NL300984I9/nl unknown
- 2019-04-30 CY CY2019023C patent/CY2019023I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR19C1017I2 (fr) | Modulateurs de transporteurs a cassette de liaison a l'atp | |
BRPI0811794A2 (pt) | "sensor de propriedade ótica" | |
DE602007006467D1 (de) | Programmierung eines multiprozessorsystems | |
BRPI0807219A2 (pt) | Composto de tiazol que modulam a atividade de hsp90 | |
DE602007008182D1 (de) | Optisches Röntgensystem | |
BRPI0922904A2 (pt) | "compostos" | |
FR2897951B3 (fr) | Detecteur d'objet | |
DK2102542T3 (da) | Nanokomposit-coatings til gevindforbindelser | |
FI20065391A0 (fi) | Anturointijärjestely | |
BRPI0813653A2 (pt) | Compostos de imidazotiazol moduladores de sirtuína | |
BRPI0921234A2 (pt) | moduladores de cassete de ligação a atp | |
BRPI0813651A2 (pt) | Compostos de tiazolopiridina moduladores de sirtuína | |
DE602007001937D1 (de) | Optischer Tomograph | |
DK1981853T3 (da) | Substituerede imidazoler samt anvendelse deraf som pesticider | |
NO20060826L (no) | Feildeteksjons-system | |
DE602008004276D1 (de) | Luftkanone | |
NO20085256L (no) | Fiberoptisk sensor for bruk på undersjøiske rørledninger | |
BRPI0912056A2 (pt) | "um fecho" | |
BRPI0813230A2 (pt) | Moduladores de calicreína 7 | |
BRPI0817915A2 (pt) | Embalagem 043 | |
DE602008005825D1 (de) | Luftdruckwaffe | |
DE602007008670D1 (de) | Winkelgeschwindigkeitsmesser | |
DE112007000530A5 (de) | Kopfplatte | |
FR2913694B1 (fr) | Elements regulateurs d'expression | |
DE602006003616D1 (de) | Optisches System |